Immuneering Corporation

NASDAQ:IMRX

Biotechnology

Healthcare
$3.46 -0.14%

-$0.01 today

Market cap
$224.08M
Beta
0.38
P/E (TTM)
-3.6
EPS (TTM)
-$1.24
52W Low $2.29High $10.08

Volume 1.25M

Average 1.38M

Returns on capital

Immuneering Corporation management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-25.6%

avg -15.1%

ROIC

-26.7%

avg -55.4%

ROA

-24.2%

avg -50.4%

Analysis

ROA is currently the strongest return metric at -24.2% versus its period average of -50.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Benjamin J. Zeskind

Co-Founder, President, Chief Executive Officer & DirectorUSD 1.08M432.32M6.38%

Brett Hall

Chief Scientific OfficerUSD 999.75K57——

Michael D. Bookman

Chief Legal Officer & SecretaryUSD 757.56K39——

Robert J. Carpenter

Co-Founder & Chair EmeritusUSD 45K8033.35K0.09%

Jyoti Joshi

Director of Quality Systems & Compliance————

Mallory Morales

Senior VP of Finance, Chief Accounting Officer & Assistant Treasurer—43140.00K0.39%

Paula George

Senior Director of Accounting & Operations and Assistant Corporate Controller————

Andrew W. Gengos

CFO & Treasurer—62——

David Caouette

Vice President of Corporate Communications————

Leah R. Neufeld

Chief People Officer—5429.60K0.08%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 23, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

7

$270,335.99

Sells

0

$0.00

Net Transaction Value

+$270,335.99

Net buying

Most Active

Hall Brett Matthew

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jun 23, 26

Zeskind Benjamin J.

Direct

Buy$10.9K
Jun 15, 26

Hall Brett Matthew

Direct

Buy$25K
Jan 16, 26

Brakewood Harold Eugene

Direct

Buy$25K
Jan 15, 26

Schall Thomas J.

Direct

Buy$101K
Jan 15, 26

Hall Brett Matthew

Direct

Buy$10.5K
Jan 13, 26

Neufeld Leah R

Direct

Buy$10.9K
Jan 12, 26

Feinberg Peter

Indirect

Buy$86.9K

Summary

Insiders reported 7 buys worth $270,335.99 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $270,335.99. Hall Brett Matthew was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Immuneering Corporation compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about IMRX's management, answered from reported figures.

Who manages IMRX?

Immuneering Corporation (IMRX) lists 10 active executives. The top listed executive is Jyoti Joshi, Director of Quality Systems & Compliance.

Are IMRX insiders buying or selling?

Recent insider activity shows net buying of $24.89M.